Symbol="RARE"
AssetType="Common Stock"
Name="Ultragenyx"
Description="Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California."
CIK="1515673"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="60 LEVERONI COURT, NOVATO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="2472842000"
EBITDA="-652508032"
PERatio="None"
PEGRatio="-0.24"
BookValue="1.806"
DividendPerShare="0"
DividendYield="0"
EPS="-9.87"
RevenuePerShareTTM="5.72"
ProfitMargin="-1.789"
OperatingMarginTTM="-1.67"
ReturnOnAssetsTTM="-0.32"
ReturnOnEquityTTM="-1.786"
RevenueTTM="402856000"
GrossProfitTTM="-370780000"
DilutedEPSTTM="-9.87"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.212"
AnalystTargetPrice="90.58"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="9.3"
PriceToBookRatio="6.8"
EVToRevenue="6.79"
EVToEBITDA="-3.744"
Beta="0.854"
num_52WeekHigh="54.98"
num_52WeekLow="33.36"
num_50DayMovingAverage="44.33"
num_200DayMovingAverage="43.01"
SharesOutstanding="70814000"
DividendDate="None"
ExDividendDate="None"
symbol="RARE"
open="37.11"
high="37.15"
low="34.88"
price="34.92"
volume="493422.00"
latest_trading_day="2023-08-17"
previous_close="37.12"
change="-2.20"
change_percent="-5.9267%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="50"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="50"
Volume_recent_avg="617043"
Change_recent_avg="-0.09"
Delta_recent_avg="1.75"
Variance_recent_avg="0.88"
Change_ratio_recent_avg="-0.24"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="50"
Aroon_momentum_negative="50"
image_negative_thumbnail_id_1="99"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0077.jpeg"
image_negative_thumbnail_id_2="110"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0066.jpeg"
image_neutral_thumbnail_id_1="537"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0062.jpeg"
image_neutral_thumbnail_id_2="529"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0070.jpeg"
image_positive_thumbnail_id_1="628"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0080.jpeg"
image_positive_thumbnail_id_2="677"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0031.jpeg"
image_professor_thumbnail_id_1="1176"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
image_professor_thumbnail_id_2="1169"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
